Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Evolva

Explore full profile

Provides products that can contribute to health, wellbeing and sensory enjoyment

Reinach, SwitzerlandFounded 2004Biotech & Life Sciences
Valuation $14M Market cap · 2026

About Evolva

Evolva, founded in 2004, is a Swiss biotechnology company that focuses on the research, development, and commercialization of natural ingredients for a variety of industries.

The company's core business revolves around its proprietary fermentation platform, which allows for the sustainable and scalable production of high-value ingredients that are traditionally sourced from plants or animals. This approach offers an alternative to synthetic ingredients and addresses the growing consumer demand for natural and sustainable products.

Evolva serves a broad range of markets, including the food and beverage, flavor and fragrance, and health and wellness sectors. Its product portfolio includes ingredients like nootkatone (a citrus flavor and fragrance), resveratrol (a polyphenol with antioxidant properties), and vanillin (a key component of vanilla flavor). The company collaborates with other businesses to develop and commercialize new ingredients, leveraging its technology platform to create customized solutions.

The business model is based on a combination of product sales, milestone payments from collaborations, and royalties on the sales of products containing its ingredients. By offering a sustainable and cost-effective production method, Evolva aims to capture a significant share of the growing market for natural ingredients.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2004
Headquarters
Reinach, Switzerland
Listing
IPO 2005
Sector
Biotech & Life Sciences

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Andrea Jansen
  • Dario Fazlic
  • Adrian Bührer
  • US Centers for Disease Control and Prevention

Series A2 investors entered at this stage

  • Aravis Ventures
  • Novartis Venture Fund

Series B and later8 investors entered at this stage

  • Heartcore Capital
  • Vinci Capital
  • Auriga Partners
  • Swisscom Ventures
  • Wellington Partners
  • BioMedVC
  • Entrepreneurs Fund
  • Nice&Green SA
Team profiled 31 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇭 Switzerland50%
🇪🇸 Spain5.6%
🇬🇧 United Kingdom5.6%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Evolva on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Evolva on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.